Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma

European Journal of Cancer

Volumn 48, Issue 9, 2012, Pages 1347-1353

  Schuetze, Scott M ^a   Zhao, Lili ^b   Chugh, Rashmi ^a   Thomas, Dafydd G ^a   Lucas, David R ^a   Metko, Gino ^c   Zalupski, Mark M ^a   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Biomarker; Bone sarcoma; Chemotherapy; mTOR inhibitor; Soft tissue sarcoma; Triglyceride

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; LIPID; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RIBOSOME PROTEIN; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DRUG DOSE ESCALATION; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; IMMUNOFLUORESCENCE; INFECTION; LIPID BLOOD LEVEL; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SARCOMA; SERUM; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RIBOSOMAL PROTEIN S6 KINASES; SARCOMA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84861335102     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.03.022     Document Type: Conference Paper

References (33)

1. R. Siegel, E. Ward, and O. Brawley Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
2. S. Sleijfer, M. Ouali, and M. van Glabbeke Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur J Cancer 46 2010 72 83
3. X. Garcia-Del-Muro, A. Lopez-Pousa, and J. Maurel Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study J Clin Oncol 29 2011 2528 2533
4. R.G. Maki, J.K. Wathen, and S.R. Patel Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected] J Clin Oncol 25 2007 2755 2763
5. G.D. Demetri, S.P. Chawla, and M. von Mehren Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 2009 4188 4196
6. D.A. Casey, L.H. Wexler, and M.S. Merchant Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience Pediatr Blood Cancer 53 2009 1029 1034
7. L.M. Wagner, N. McAllister, and R.E. Goldsby Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma Pediatr Blood Cancer 48 2007 132 139
8. R.L. Saylors 3rd, K.C. Stine, and J. Sullivan Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study J Clin Oncol 19 2001 3463 3469
9. C.L. Sawyers Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4 2003 343 348
10. E. Hernando, E. Charytonowicz, and M.E. Dudas The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nat Med 13 2007 748 753
11. A.J. Wagner, I. Malinowska-Kolodziej, and J.A. Morgan Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors J Clin Oncol 28 2010 835 840
12. M.W. Albers, R.T. Williams, and E.J. Brown FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line J Biol Chem 268 1993 22825 22829
13. P.J. Houghton, C.L. Morton, and E.A. Kolb Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Pediatr Blood Cancer 50 2008 799 805
14. S. Mateo-Lozano, O.M. Tirado, and V. Notario Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation Oncogene 22 2003 9282 9287
15. X. Wan, N. Shen, and A. Mendoza CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling Neoplasia 8 2006 394 401
16. O.M. Tirado, S. Mateo-Lozano, and V. Notario Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity Oncogene 24 2005 3348 3357
17. M. Guba, P. von Breitenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128 135
18. A. Jimeno, M.A. Rudek, and P. Kulesza Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors J Clin Oncol 26 2008 4172 4179
19. S. Okuno, H. Bailey, and M.R. Mahoney A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C) Cancer 117 2011 3468 3475
20. S.P. Chawla, A.P. Staddon, and L.H. Baker Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas J Clin Oncol 30 2012 78 84
21. P.J. Houghton, C.L. Morton, and R. Gorlick Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program Mol Cancer Ther 9 2010 101 112
22. R. Chugh, J.K. Wathen, and R.G. Maki Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model J Clin Oncol 27 2009 3148 3153
23. A. Nocito, J. Kononen, and O.P. Kallioniemi Tissue microarrays (TMAs) for high-throughput molecular pathology research Int J Cancer 94 2001 1 5
24. A. McCabe, M. Dolled-Filhart, and R.L. Camp Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis J Natl Cancer Inst 97 2005 1808 1815
25. H.R. Dhaini, D.G. Thomas, and T.J. Giordano Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma J Clin Oncol 21 2003 2481 2485
26. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
27. M. Van Glabbeke, J. Verweij, and I. Judson Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 38 2002 543 549
28. O. Mir, J. Domont, and A. Cioffi Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma Eur J Cancer 47 2011 515 519
29. M.M. Mita, A.C. Mita, and Q.S. Chu Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol 26 2008 361 367
30. R. Quek, Q. Wang, and J.A. Morgan Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors Clin Cancer Res 17 2011 871 879
31. V.P. Houde, S. Brule, and W.T. Festuccia Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue Diabetes 59 2010 1338 1348
32. J.D. Morrisett, G. Abdel-Fattah, and R. Hoogeveen Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients J Lipid Res 43 2002 1170 1180
33. O.H. Iwenofu, R.D. Lackman, and A.P. Staddon Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy Mod Pathol 21 2008 231 237